|Delayed - 06/11 04:00:00 pm|
Vir Biotechnology : Reminds Stockholders of 2021 Annual General Meeting Details
|05/10/2021 | 04:06pm|
Vir Biotechnology’s stockholders of record as of March 22, 2021 (the “Record Date”), can attend and vote at the Annual Meeting by accessing the meeting center at http://www.virtualshareholdermeeting.com/VIR2021 and entering the control number on the proxy card or Notice of Internet Availability of Proxy Materials previously received. Instructions on how to connect to the Annual Meeting and participate via the Internet are also posted at http://www.virtualshareholdermeeting.com/VIR2021. Online access to the Annual Meeting will begin at 11:15 a.m. PT. Stockholders should allow ample time for the check-in procedures.
Whether or not stockholders plan to virtually attend the Annual Meeting, Vir Biotechnology urges them to vote and submit their proxy in advance of the Annual Meeting by one of the methods described in the proxy materials for the Annual Meeting.
Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B virus, influenza A and human immunodeficiency virus. For more information, please visit www.vir.bio.
VP, Head of Investor Relations
VP, Corporate Communications
2021 GlobeNewswire, Inc., source